Insurer Highmark Partners With Soleo Health for Hemophilia Care, Management

Insurer Highmark Partners With Soleo Health for Hemophilia Care, Management

Citing Soleo Health’s clinical expertise and data-reporting capabilities, U.S. national insurer Highmark has tapped the specialty pharmacy and infusion services provider to help care for its members who have hemophilia.

An independent licensee of the Blue Cross Blue Shield Association, Highmark covers about 190 hemophilia patients. The agreement with Soleo, one of three Highmark providers, begins Jan. 1, 2020. The insurer spends roughly $80 million each year on care for hemophiliacs, some 90% in pharmacy costs.

The pact calls for Soleo Health to care for these members through its 20 therapeutic care management centers across the nation that are dedicated to bleeding disorders. Each center is staffed with trained interdisciplinary teams consisting of specially taught pharmacists, registered nurses, clinical nurse educators, local resource advocates, and reimbursement specialists. These staffers treat and manage both hemophilia types, A and B, as well as Von Willebrand disease and other bleeding disorders.

Highmark will use SoleMetrics — Soleo Health’s proprietary, evidence-based, data-driven clinical outcomes program, which is designed to enhance the care of those with complex or chronic conditions such as hemophilia. The interdisciplinary program provides customized detail reporting by patient therapy, disease state, physician, payor, pharmaceutical manufacturer, and accountable care organization. The insurer can use the program’s hemophilia-specific data to gauge clinical and economic value to Highmark, providers, and patients.

“Soleo Health was selected as a preferred provider partner to manage our hemophilia patients, based on the exemplary care it delivers as well as its extraordinary outcomes and data capabilities,” Sean Burke, manager, Highmark specialty pharmacy services, said in a press release. “Highmark wanted to develop a program that delivered exceptional value-based care to our patients, and recognized the best way to do this was to partner with physician specialists and infusion providers.”

Burke said Highmark sought to link members with providers experienced in hemophilia management.

“Our priority lies in taking a highly personalized and therapeutic focused approach to providing superior patient management and clinical care,” said Drew Walk, Soleo Health’s CEO. “We continue to garner preferred relationships with payors and health systems as well as pharmaceutical manufacturers based on our clinical expertise and distinctive, real-world evidence data reporting.”

“We are positively affecting the quality of care we bring the patients, payors, and providers with whom we care for and work,” Walk added.

According to the Centers for Disease Control and Prevention, hemophilia occurs in about one of every 5,000 male births.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 121
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Highmark hemophilia partnership
  • coagulation test, hemophilia
  • research and women
  • SB-525 ALTA trial

Pin It on Pinterest

Share This